Remote Ischemic Preconditioning in Type 2 Diabetic Patients Undergoing CABG

Launched by MUĞLA SITKI KOÇMAN UNIVERSITY · May 14, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a technique called remote ischemic preconditioning (RIPC) to see if it can help protect the heart during surgery for patients with type 2 diabetes who are having coronary artery bypass graft (CABG) surgery. The study is important because people with diabetes are at higher risk for heart damage during this type of surgery. RIPC is a simple and safe method that involves using a cuff on the arm to temporarily restrict blood flow. This may help the heart better tolerate the stress of surgery.

To participate in the trial, patients must be between 40 and 85 years old, have type 2 diabetes that is being treated, and be scheduled for elective CABG surgery. Those who have certain health issues, such as severe heart problems or kidney failure, will not be eligible. If patients join, they will either receive RIPC before their surgery or standard care. Researchers will monitor their heart health after surgery to see if RIPC makes a difference in reducing heart injury and other complications. This study aims to understand how RIPC might help improve outcomes for diabetic patients undergoing heart surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with type 2 diabetes mellitus and receiving medical treatment
• • Scheduled for isolated elective coronary artery bypass graft (CABG) surgery
• • American Society of Anesthesiologists (ASA) physical status class III or IV
• • Age between 40 and 85 years
• Exclusion Criteria:
• • Emergency CABG surgery Reoperation (revision surgery) Left ventricular ejection fraction (LVEF) \< 40% History of cardiac arrest or cardiogenic shock Pregnancy Clinically significant peripheral arterial disease affecting the upper limbs Hepatic dysfunction (bilirubin \> 20 μmol/L or INR \> 2.0) Renal failure (eGFR \< 20 mL/min/1.73 m²) Ongoing treatment with glibenclamide or nicorandil (agents known to interfere with ischemic preconditioning mechanisms) Asthma